List of Excipients in Branded Drug BASIC CARE MICONAZOLE 7

« Back to Dashboard

Generic Drugs Containing BASIC CARE MICONAZOLE 7

Company	Ingredient	NDC	Excipient
L Perrigo Company	miconazole nitrate	0113-7825	BENZOIC ACID
L Perrigo Company	miconazole nitrate	0113-7825	BUTYLATED HYDROXYANISOLE
L Perrigo Company	miconazole nitrate	0113-7825	GLYCERYL MONOSTEARATE
L Perrigo Company	miconazole nitrate	0113-7825	MINERAL OIL

What are the Most Frequently-Used Excipients in BASIC CARE MICONAZOLE 7?

# Of NDCs	Excipient
2	BENZOIC ACID
2	BUTYLATED HYDROXYANISOLE
2	GLYCERYL MONOSTEARATE
2	MINERAL OIL

Basic Care Miconazole 7: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

Basic Care Miconazole 7 is a seven-day vaginal antifungal product containing miconazole nitrate 2% in a cream dosage form. Its commercial position is driven by OTC monograph eligibility, private-label pricing, retailer distribution, and patient-use characteristics rather than by an exclusive patent estate. The main excipient opportunities are improved leakage control, applicator delivery, irritation reduction, preservative robustness, and package differentiation.

What is Basic Care Miconazole 7?

Basic Care Miconazole 7 is an OTC vaginal cream for treatment of vaginal yeast infections. The product contains:

Product attribute	Basic Care Miconazole 7
Active ingredient	Miconazole nitrate 2%
Dosage form	Vaginal cream
Treatment duration	Seven days
Route	Intravaginal
Delivery system	Single-use vaginal applicators
Regulatory pathway	OTC vaginal antifungal monograph
Prescription requirement	None
Biosimilar relevance	None
Orange Book relevance	Generally not applicable to monograph-listed OTC products

The product is positioned against branded and generic miconazole products, including Monistat 7 and retailer-branded miconazole nitrate 2% creams. The commercial product is typically sold as a carton containing a tube of cream and seven disposable applicators. Exact package configuration, NDC, distributor, and inactive-ingredient declaration should be tied to the specific marketed label because private-label products can change manufacturers or packaging suppliers.

The labeled inactive ingredients commonly associated with this product presentation are benzoic acid, mineral oil, and purified water. The excipient system is a relatively simple cream base compared with more complex emulsion or polymeric vaginal delivery systems. [1]

What excipients are used in Basic Care Miconazole 7?

The principal publicly listed excipients are:

Excipient	Likely functional role	Commercial significance
Benzoic acid	Preservative and pH-control component	Supports microbiological quality in a water-containing product
Mineral oil	Emollient and oil-phase vehicle	Provides lubricity and cream body
Purified water	Continuous or dispersed aqueous phase	Controls rheology, spreadability, and patient feel

The product’s excipient strategy appears designed for low-cost manufacture, acceptable vaginal application, and adequate physical stability. Mineral oil contributes to occlusivity and lubrication. Benzoic acid supports preservation but can affect local tolerability and pH. Purified water provides the aqueous phase needed for cream formation and drug dispersion.

Benzoic acid and preservative strategy

Benzoic acid is a conventional preservative for acidic aqueous systems. Its antimicrobial activity depends on pH because the unionized form has greater preservative activity than the ionized form. A formulation developer must therefore control pH, water activity, microbial burden, and packaging compatibility.

Potential development issues include:

• Local stinging or irritation in sensitive users.
• Reduced preservative effectiveness if pH drifts upward.
• Interaction with packaging materials or closure systems.
• Preservative loss through adsorption or partitioning into the oil phase.
• Need for preservative effectiveness testing under applicable compendial or regulatory methods.

A reformulator should not assume that replacing benzoic acid with another preservative will be commercially neutral. The replacement may change tolerability, microbial control, pH, regulatory support, and product labeling.

Mineral oil and vaginal cream performance

Mineral oil is inexpensive, chemically stable, and compatible with many topical cream systems. It can improve lubrication and reduce friction during administration. Its limitations include:

• Potential leakage after application.
• Oily residue and staining.
• Variable patient perception of cleanliness.
• Possible compatibility concerns with latex contraceptive products.

Miconazole vaginal products commonly carry warnings relating to interaction with condoms and diaphragms. A formulation or packaging change that materially affects latex compatibility could have regulatory and labeling consequences. [2]

Purified water and microbiological control

Water-containing vaginal creams require control of microbial contamination during manufacture and throughout shelf life. The formulation must maintain:

• Consistent pH.
• Adequate preservative concentration.
• Stable viscosity.
• Low microbial burden.
• Compatibility with the tube and applicator.
• Adequate drug content uniformity.

Water activity and emulsion structure are important commercial variables. A cream that is microbiologically stable but separates, thins, or leaks can produce poor consumer reviews and higher returns.

What formulation patents protect miconazole vaginal cream?

No product-specific patent estate is apparent from the public OTC monograph positioning of Basic Care Miconazole 7. The active ingredient, miconazole nitrate, is an established generic antifungal. A standard miconazole nitrate 2% vaginal cream is unlikely to depend on a currently enforceable composition-of-matter patent.

The relevant IP categories are more likely to involve:

1. Specialized delivery systems

   • Bioadhesive vaginal gels.
   • Mucoadhesive polymers.
   • Sustained-release inserts.
   • Liposomal or nanoemulsion systems.
   • Thermoresponsive gels.

2. Alternative formulations

   • Lower-irritation creams.
   • Anhydrous or low-water systems.
   • Foam or gel formulations.
   • Combination antifungal and symptom-relief products.
   • Enhanced-solubility systems.

3. Applicator and packaging patents

   • Controlled-dose applicators.
   • No-touch applicators.
   • Reduced-leakage applicators.
   • Applicators with depth-limiting structures.
   • Single-use systems designed to reduce contamination.

4. Manufacturing processes

   • Improved particle-size control.
   • Drug dispersion methods.
   • Emulsion processing.
   • De-aeration and filling methods.
   • Container-closure systems that improve stability.

A conventional miconazole 2% cream using common excipients generally has limited patent differentiation. Patent value increases when the formulation produces a measurable technical effect, such as improved retention, lower leakage, better drug release, reduced irritation, or improved stability.

What is the Orange Book status of Basic Care Miconazole 7?

Basic Care Miconazole 7 is generally not an Orange Book-listed prescription drug product. The Orange Book primarily identifies approved prescription drug products and certain approved OTC products that originated under an NDA pathway. Products marketed under an OTC monograph are not normally supported by Orange Book-listed patents or exclusivity in the same manner as NDA products. [3]

This means:

• No conventional Orange Book patent-listing strategy is expected.
• A Paragraph IV challenge is generally not the central entry mechanism.
• Abbreviated new drug application litigation is not the ordinary competitive framework.
• Market entry depends more on monograph compliance, manufacturing capability, labeling, quality systems, and retailer access.

A company seeking to commercialize a comparable product would usually evaluate OTC monograph compliance rather than relying on an ANDA against Basic Care Miconazole 7.

When does Basic Care Miconazole 7 lose exclusivity?

Basic Care Miconazole 7 does not appear to have a meaningful product-specific exclusivity period. Its market protection is based on brand placement, retailer relationships, supply reliability, and consumer recognition.

The product is exposed to immediate competition from:

• Monistat 7.
• Generic miconazole nitrate 2% vaginal creams.
• Other miconazole dosage forms.
• Clotrimazole vaginal products.
• Tioconazole one-dose products.
• Fluconazole prescription therapy, where clinically appropriate.

The absence of meaningful exclusivity creates a low legal barrier to entry. The commercial barrier is operational: qualifying a stable cream, sourcing applicators, passing quality testing, meeting OTC labeling requirements, and obtaining retailer distribution.

Are Paragraph IV challenges relevant to miconazole 7?

Paragraph IV litigation is not the primary risk mechanism for a monograph-listed product. A competitor would not normally need to challenge a Basic Care patent to market a compliant miconazole 2% vaginal cream.

The key regulatory requirements are instead:

• Use of an eligible active ingredient and concentration.
• Compliance with the applicable vaginal antifungal monograph.
• Appropriate Drug Facts labeling.
• Manufacturing under current good manufacturing practice requirements.
• Stability and microbiological quality data.
• Adequate container-closure and applicator controls.
• Advertising and claims consistent with the authorized OTC indication.

The legal exposure shifts from patent infringement to regulatory noncompliance, trade dress, trademark, false advertising, product liability, and contract disputes.

What FDA regulatory status applies to Basic Care Miconazole 7?

Miconazole nitrate vaginal products are regulated as OTC vaginal antifungal products. FDA’s OTC monograph framework permits marketing when the product meets applicable conditions, including active ingredient, strength, dosage form, route, indications, warnings, directions, and labeling requirements. [2,4]

The product must communicate important consumer instructions, including:

• Use for the labeled seven-day treatment course.
• External use of the cream only as directed.
• Consultation with a healthcare professional for first-time symptoms, pregnancy, recurrent infections, fever, abdominal pain, or malodorous discharge.
• Warnings concerning condom and diaphragm use.
• Discontinuation and medical consultation if symptoms persist or worsen.

A reformulated product must be assessed for whether excipient changes affect the product’s quality, safety, performance, labeling, or monograph status. A new preservative, a different applicator, a change in drug concentration, or a new claim can materially change the regulatory analysis.

What commercial opportunities exist for excipient innovation?

The strongest opportunities are incremental improvements that preserve monograph eligibility while solving recognized patient-use problems.

Reduced-leakage cream

A higher-yield or more structured cream could improve retention after administration. Potential approaches include:

• Controlled-viscosity oil-in-water emulsions.
• Weakly mucoadhesive polymers.
• Reduced-creep mineral-oil systems.
• Bioadhesive excipients at low concentrations.
• Temperature-responsive rheology.

The formulation must avoid excessive residue, difficult extrusion, or altered drug release.

Lower-irritation formulation

A low-irritation product could compete on tolerability. Development variables include:

• Lower preservative burden where feasible.
• pH optimization.
• Reduced surfactant load.
• Alternative emollients.
• Removal of unnecessary fragrance or sensory agents.
• Control of osmolality and local tissue irritation.

Because vaginal tissue can be sensitive during infection, tolerability may influence repeat purchases and retailer ratings.

Improved applicator performance

The applicator is a major commercial opportunity even when the cream composition remains conventional. Improvements could include:

• More consistent delivered volume.
• Ergonomic grip.
• Reduced residual cream after dose delivery.
• Rounded, low-trauma insertion geometry.
• Depth limitation.
• Better tube-to-applicator connection.
• Lower plastic use.
• Packaging that reduces contamination during repeated tube access.

A redesigned applicator may create protectable utility or design rights, but it must remain compatible with dose accuracy and consumer instructions.

Clean-label and sustainability positioning

A retailer could differentiate the product through:

• Lower-plastic packaging.
• Paperboard reduction.
• Recyclable applicators where feasible.
• Reduced petroleum-derived excipients.
• Plant-derived emollients.
• Simplified inactive-ingredient labeling.

These claims require substantiation. A “natural,” “clean,” or “eco-friendly” position can create advertising risk if the claim is broader than the documented product attributes.

How does Basic Care Miconazole 7 compare with competing products?

Product category	Typical regimen	Main commercial advantage	Main weakness
Miconazole 7 cream	Seven days	Familiar active and lower daily dose burden	Longer treatment and leakage
Miconazole 3 cream or suppository	Three days	Shorter course	Potentially higher unit price
Tioconazole one-dose ointment	One dose	Convenience	Different formulation feel and price
Clotrimazole vaginal products	Multiple regimens	Broad generic availability	Less dominant U.S. consumer recognition
Prescription fluconazole	Usually oral single dose	Convenience and no intravaginal administration	Prescription access and clinical restrictions

Basic Care’s likely competitive advantage is price. Its principal disadvantages are the seven-day regimen, cream residue, applicator inconvenience, and weak brand differentiation.

What generic launch risks exist for Basic Care Miconazole 7?

Generic and private-label entry risk is high because the product category has limited exclusivity. The principal launch risks are operational rather than patent-related.

Risk	Impact	Mitigation
Cream separation	Product rejection, returns, poor ratings	Accelerated and real-time stability testing
Inconsistent applicator fill	Dose variability and complaints	Automated filling and delivery-volume controls
Preservative failure	Microbiological risk	Preservative effectiveness and microbial-limit testing
Excessive leakage	Low consumer satisfaction	Rheology and retention optimization
Latex incompatibility	Safety and labeling exposure	Compatibility testing and clear warnings
Labeling deviation	Regulatory action	Monograph-based label review
Supply interruption	Retail delisting	Dual-source excipients and applicators
Packaging changes	Stability or compatibility failure	Container-closure qualification

How strong is the patent estate for Basic Care Miconazole 7?

The patent estate is weak for a conventional miconazole nitrate 2% vaginal cream. The active ingredient is generic, the dosage form is established, and the product is positioned under the OTC monograph framework. Defensible IP would more likely attach to an improved delivery system, applicator, manufacturing process, or packaging architecture.

A practical freedom-to-operate review should focus on:

• Adhesive vaginal delivery systems.
• Sustained-release miconazole products.
• Applicator mechanisms.
• Single-dose or no-touch delivery devices.
• Low-irritation preservative systems.
• Bioadhesive or thermoresponsive compositions.
• Container-closure and filling technologies.

Trademark and trade-dress clearance is also important because a competing retailer product may resemble an established private-label package without copying protected brand elements.

What licensing deals could support a miconazole 7 opportunity?

A conventional product may not require a drug-technology license. Licensing opportunities are more relevant to differentiated components:

• A patented low-leakage vaginal cream base.
• A mucoadhesive delivery platform.
• A proprietary applicator.
• A contract-manufacturing arrangement with validated miconazole capabilities.
• A private-label supply agreement with a national retailer.
• A sustainable packaging technology.

The most commercially attractive structure is likely a supply or co-development agreement rather than a royalty-bearing license on ordinary miconazole cream technology. Royalty economics would be difficult to support unless the licensed technology produced a measurable price premium, higher repeat purchase, or retailer exclusivity.

What revenue exposure does miconazole 7 have?

Product-specific revenue for Basic Care Miconazole 7 is not publicly disclosed in standard public-company reporting. The relevant exposure is category-based:

• Seasonal demand linked to OTC vaginal antifungal purchasing.
• High price sensitivity.
• Strong retailer influence.
• Substitution among treatment durations.
• Competition from branded, generic, and prescription products.
• Limited switching costs.
• Low protection from patents or regulatory exclusivity.

A formulation improvement would need to justify either a higher retail price, improved retailer margin, stronger search conversion, lower return rates, or a differentiated claim. Cost reduction alone may be more valuable in a private-label setting than a premium formulation.

Key Takeaways

• Basic Care Miconazole 7 is a miconazole nitrate 2% seven-day vaginal cream.
• Its commercial protection comes from price, distribution, and retailer placement, not meaningful product exclusivity.
• The core excipients are commonly listed as benzoic acid, mineral oil, and purified water.
• The highest-value formulation opportunities involve leakage, irritation, rheology, applicator performance, and packaging.
• Paragraph IV litigation and Orange Book patent disputes are generally not central to this OTC monograph product.
• A competing product can likely enter without overcoming a product-specific patent barrier, provided it satisfies FDA OTC requirements.
• The strongest defensible IP would attach to an improved cream, delivery system, applicator, or manufacturing process.
• A private-label or contract-manufacturing strategy is more commercially plausible than a conventional patent-license strategy.

FAQs

Is Basic Care Miconazole 7 the same as Monistat 7?

Both products use miconazole nitrate 2% in a seven-day vaginal treatment format, but inactive ingredients, applicators, packaging, manufacturer, and retail pricing may differ.

Can a company market a private-label miconazole 7 cream without an ANDA?

A product that meets the applicable OTC vaginal antifungal monograph conditions may be marketed without relying on an ANDA against the Basic Care product. The sponsor remains responsible for manufacturing, labeling, quality, stability, and regulatory compliance.

Which excipient is most important for miconazole vaginal cream stability?

No single excipient controls performance. The interaction between preservative concentration, pH, oil-water structure, viscosity, packaging, and microbial quality determines stability.

Can miconazole vaginal cream be reformulated with plant-derived oils?

It may be technically feasible, but the substitute oil can change drug distribution, preservative partitioning, viscosity, leakage, odor, stability, and latex compatibility. Each change requires formulation and regulatory assessment.

Is an applicator patent more valuable than a cream-composition patent for miconazole 7?

For a conventional OTC monograph product, an applicator patent may offer more practical differentiation because the active ingredient and basic cream format are established. Its value depends on dose accuracy, comfort, leakage reduction, manufacturability, and freedom to operate.

References

1. DailyMed. (n.d.). Basic Care Miconazole 7: Miconazole nitrate 2% vaginal cream. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). OTC monograph for vaginal antifungal drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 333: Topical antimicrobial drug products for over-the-counter human use. https://www.ecfr.gov/